<DOC>
	<DOCNO>NCT00524771</DOCNO>
	<brief_summary>The objective study characterize compare risk short- long-term use NuvaRing® market combined oral contraceptive .</brief_summary>
	<brief_title>Transatlantic Active Surveillance Cardiovascular Safety NuvaRing ( TASC )</brief_title>
	<detailed_description>This large , multinational , control , prospective , active surveillance study woman prescribe NuvaRing® oral contraceptive ( OC ) . The study follow two cohort . The cohort consist new user ( starter switcher ) two different group hormonal contraceptive : - NuvaRing® - market combined OCs ( combine oral contraceptive ) NuvaRing® transparent flexible contraceptive vaginal ring contain etonogestrel ethinylestradiol ( EE ) . The ring release 15 mcg EE 120 mcg etonogestrel daily . After insertion remain upper part vagina 21 day , follow 7 ring-free day new ring insert . The primary objective study characterize compare risk short- long-term use NuvaRing® market combined OCs . The main clinical outcome interest short long-term follow-up : - Deep Venous Thrombosis ( DVT ) - Pulmonary Embolism ( PE ) - Acute Myocardial Infarction ( AMI ) - Cerebrovascular Accidents ( CVA ) Secondary objective : - analyze drug utilization pattern NuvaRing® market OCs study population representative typical use individual contraceptive method routine medical condition - characterize baseline risk user individual formulation - ass compliance NuvaRing® users user market OCs - analyze reason discontinue treatment NuvaRing® and/or market OCs . The study use non-interference approach provide standardize , comprehensive , reliable information treatment routine clinical practice set . Study participant recruit via international network 1000 gynecologist . After study entry cohort member follow period 30 48 month rare serious safety outcome . Regular , active contact cohort member study team Berlin Center Epidemiology Health Research ( ZEG ) , Germany provide necessary information health-related event change health status ( = active surveillance ) . Approximately 15,000 subject per cohort recruit participate physician order provide approx . 86,000 women-years ( WY ) observation . Subjects consider enrollment study participate physician determine NuvaRing® OC use appropriate . There specific inclusion/exclusion criterion . All woman eligible asked physician willing participate . As non-interventional study , possibility participate study discuss patient - physician patient - agree upon prescription . The study conduct several European country United States . The study divide 2 phase : baseline survey include initial consultation baseline participate physician , follow-up phase include two follow-up contact within first year annual follow-up contact 4 year post-baseline . The study maintain scientific independence govern independent Safety Monitoring Advisory Council ( SMAC ) . The Berlin Center Epidemiology Health Research ( ZEG ) research team accountable council scientific matter . The member council international expert relevant scientific field ( e. g. , epidemiology , drug safety , gynecology , cardiology , statistic , endocrinology ) .</detailed_description>
	<criteria>woman prescribe NuvaRing® combine oral contraceptive new user ( Starters , restarters switcher ) formulation woman consent participate study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Contraceptive Vaginal Ring</keyword>
</DOC>